Among the body's most ancient challenges is knowing when to stop fighting — when the alarm of inflammation must give way to quiet repair. Researchers at the University of Strasbourg have identified a synthetic polymer, PAR30, that may help the immune system find that moment more reliably, guiding neutrophils toward a timely, orderly death and making their removal by the body's cleanup cells more efficient. The discovery, published in Nature, does not silence the immune system but instead helps it complete its own natural arc — from alarm to resolution — with greater precision. In a landscape o
Novel polymer PAR30 shows promise in controlling inflammation by triggering neutrophil death
A polymer that makes dying neutrophils easier to clean up
Mark
So PAR30 kills neutrophils. Isn't that risky? Don't we need neutrophils?
Mimi
We do, but only at the right time. Neutrophils are essential for fighting infection, but they're also supposed to die once the job is done. The problem is when they don't die on schedule—then they damage healthy tissue. PAR30 accelerates the natural process.
Luke
The study shows this works in the lab. Do we know yet if it works in living organisms, in actual patients?
Mimi
The paper focuses on the cellular mechanism. That's the foundation. Animal models and clinical trials would come next.
Mark
You mentioned macrophages recognize these PAR30-treated neutrophils better. Why does that matter?
Mimi
Dead cells left lying around trigger more inflammation. If macrophages clear them faster, the inflammatory response resolves more cleanly. It's the difference between a controlled shutdown and a messy one.
Luke
The thiolated version showed promise in preliminary tests. But "preliminary" is doing a lot of work there. How many cells were tested? What's the sample size?
Mimi
The paper doesn't provide those granular details in the sections available. That's a fair question for the full methods.
Mark
If this works, what diseases would benefit most?
Mimi
Chronic inflammatory conditions where the body can't turn off the alarm—rheumatoid arthritis, inflammatory bowel disease, conditions where inflammation itself becomes the disease.
Luke
And the funding came from multiple countries and EU programs. That suggests serious institutional backing, which is good. But it also means we should wait for independent replication before calling this a breakthrough.
Mimi
Absolutely. This is promising early-stage science. The mechanism is solid, the preliminary results are encouraging, but the path from lab to clinic is long.
The Pulse
- When neutrophils linger past their purpose, inflammation can calcify into chronic disease — and current therapies often blunt the immune system broadly rather than resolving the underlying logjam.
- PAR30, a chain of thirty arginine units, disrupts this stalemate by entering neutrophils and triggering their mitochondria to produce reactive oxygen species, setting off a controlled self-dismantling sequence through caspase activation.
- Critically, neutrophils that die in PAR30's presence are more readily recognized and consumed by macrophages, meaning the polymer accelerates not just cell death but the body's own cleanup — a two-stage improvement in inflammatory resolution.
- A chemically modified version, thiolated-PAR30, showed even stronger apoptotic effects in early tests, suggesting the compound's potency can be tuned through structural refinement.
- The research, backed by European and national funding bodies, positions PAR30 as a potential forerunner of a new therapeutic class — one that works with inflammation's natural resolution pathway rather than overriding it.
Among the body's most ancient challenges is knowing when to stop fighting — when the alarm of inflammation must give way to quiet repair. Researchers at the University of Strasbourg have identified a synthetic polymer, PAR30, that may help the immune system find that moment more reliably, guiding neutrophils toward a timely, orderly death and making their removal by the body's cleanup cells more efficient. The discovery, published in Nature, does not silence the immune system but instead helps it complete its own natural arc — from alarm to resolution — with greater precision. In a landscape of chronic inflammatory disease, this distinction may prove to be a meaningful one.
Neutrophils are the immune system's first responders, but they carry a built-in expiration date. When that deadline is missed — when dead or dying neutrophils accumulate without being cleared — inflammation can persist long after the original threat has passed, causing tissue damage and contributing to chronic disease. A research team has now identified a synthetic polymer, PAR30, that appears to help the body honor that deadline more reliably.
Constructed from thirty arginine subunits, PAR30 works by initiating apoptosis — a controlled, orderly form of cell death — inside neutrophils. The polymer targets the cell's mitochondria, prompting them to release reactive oxygen species that in turn activate caspases 3 and 7, the molecular executors of the apoptotic program. Because the process is contained rather than explosive, the dying cell does not rupture and spill inflammatory material into surrounding tissue.
Equally important is what happens next. Neutrophils that die in the presence of PAR30 are more efficiently recognized and engulfed by macrophages — the immune cells tasked with clearing cellular debris. This enhanced efferocytosis means PAR30 improves both stages of inflammatory resolution: the death of the neutrophil and its subsequent removal.
The researchers also tested a chemically modified version, thiolated-PAR30, which demonstrated an even stronger pro-apoptotic effect in preliminary experiments, suggesting that further refinements to the polymer's structure could improve its cellular penetration and therapeutic reach.
Supported by the French government's Investments for the Future Program, the European Union's Horizon Europe Framework, and partners from Switzerland and the United Kingdom, the work emerged from the Interdisciplinary Institute HiFunMat at the University of Strasbourg. Rather than broadly suppressing immune function — the approach of many existing anti-inflammatory drugs — PAR30 points toward a strategy of acceleration: helping the body complete its own inflammatory resolution more efficiently, a distinction that could matter greatly for conditions where that resolution has stalled.
Neutrophils are the body's first responders to injury and infection, but they also need to die on schedule. When inflammation lingers because dead neutrophils aren't cleared away efficiently, the result is tissue damage and chronic disease. A research team has identified a synthetic polymer called PAR30—made of thirty arginine subunits strung together—that appears to accelerate this necessary cell death and improve how the body's cleanup crew handles the aftermath.
The polymer works by triggering what scientists call apoptosis, a controlled form of cell death. When PAR30 encounters neutrophils in the lab, it sets off a cascade inside the cell's mitochondria, the energy-producing organelles that also serve as a control center for cell fate. The polymer causes these mitochondria to produce reactive oxygen species, chemically reactive molecules that act as a signal. This signal activates two enzymes called caspases 3 and 7, which execute the apoptotic program—essentially telling the neutrophil to disassemble itself in an orderly way. The process is clean and contained, which matters because it prevents the cell from rupturing and spilling inflammatory contents into surrounding tissue.
But triggering neutrophil death is only half the problem. The other half is getting rid of the dead cells before they become a liability. Here the research revealed something encouraging: neutrophils that had undergone apoptosis in the presence of PAR30 were recognized and engulfed more readily by macrophages, the immune cells responsible for cleaning up cellular debris. This enhanced recognition and clearance—a process called efferocytosis—suggests that PAR30 doesn't just kill neutrophils; it makes them easier to remove. The combination amounts to a more efficient resolution of inflammation, the body's natural way of turning off the alarm once the threat has passed.
The researchers also explored whether chemical modifications could make PAR30 work even better. They added thiol groups to the polymer, creating a version called thiolated-PAR30. In preliminary tests, this modified version showed an even stronger pro-apoptotic effect, measured by increased annexin-V staining, a standard marker of apoptotic cells. The finding suggests that fine-tuning the polymer's chemistry could enhance its ability to penetrate cells and trigger the desired response.
The work was supported by funding from multiple sources, including the French government's Investments for the Future Program, the European Union's Horizon Europe Framework, and joint funding from Switzerland and the United Kingdom. The research emerged from the Interdisciplinary Institute HiFunMat at the University of Strasbourg, involving collaboration with the Lymphocyte Homeostasis and Autoimmunity team and other institutional partners. The findings point toward a new class of anti-inflammatory drugs—compounds that don't suppress the immune system broadly but instead accelerate the resolution phase of inflammation by promoting neutrophil death and improving cellular clearance. For diseases where inflammation becomes stuck in a chronic state, this approach could offer a fundamentally different therapeutic strategy than current options.
Notable Quotes
PAR30-based compounds appear as novel anti-inflammatory agents, capable of promoting neutrophil apoptosis and enhancing macrophage-mediated clearance, paving the way for therapeutic applications in difficult-to-treat inflammatory diseases.— Research findings from the study
Want the full story?
Read the original at Nature ↗